Benitec Biopharma Inc.
BNTCNASDAQHealthcare● Active
$10.61
+$0.06(+0.57%)
Market Cap$278481158
P/E Ratio—
52W High$17.15
52W Low$9.85
Benitec Biopharma Inc. (BNTC) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BNTC · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$0.24
Est. -$0.27 · +11.1%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
BNTC reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Sep 30, 2026 | -$0.28 | — | — | — | $0.01B | — |
| ◌ Q3 FY2026 | Sep 28, 2026 | -$0.25 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 14, 2026 | -$0.27 | -$0.24 | +11.1% | — | $0.00B | — |
| ▼ Q1 FY2026 | Feb 12, 2026 | -$0.23 | -$0.26 | -13.0% | — | — | — |
| ▲ Q4 FY2025 | Nov 14, 2025 | -$0.35 | -$0.22 | +37.1% | — | — | — |
| ▼ Q3 FY2025 | Sep 22, 2025 | -$0.28 | -$0.42 | -50.0% | $0.00B | — | — |
| ▲ Q2 FY2025 | May 14, 2025 | -$0.36 | -$0.24 | +33.3% | — | — | — |
| ▲ Q1 FY2025 | Feb 14, 2025 | -$1.00 | -$0.36 | +64.0% | — | — | — |
Q3 FY2026
Sep 30, 2026
EPS Actual
—
EPS Est.
-$0.28
EPS Surpr.
—
Revenue
—
Q3 FY2026
Sep 28, 2026
EPS Actual
—
EPS Est.
-$0.25
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Beat
EPS Actual
-$0.24
EPS Est.
-$0.27
EPS Surpr.
+11.1%
Revenue
—
Q1 FY2026
Feb 12, 2026Miss
EPS Actual
-$0.26
EPS Est.
-$0.23
EPS Surpr.
-13.0%
Revenue
—
Q4 FY2025
Nov 14, 2025Beat
EPS Actual
-$0.22
EPS Est.
-$0.35
EPS Surpr.
+37.1%
Revenue
—
Q3 FY2025
Sep 22, 2025Miss
EPS Actual
-$0.42
EPS Est.
-$0.28
EPS Surpr.
-50.0%
Revenue
$0.00B
Q2 FY2025
May 14, 2025Beat
EPS Actual
-$0.24
EPS Est.
-$0.36
EPS Surpr.
+33.3%
Revenue
—
Q1 FY2025
Feb 14, 2025Beat
EPS Actual
-$0.36
EPS Est.
-$1.00
EPS Surpr.
+64.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2027 | $0.05 | $0.05 | $0.05 | 1 |
| Q1 FY2027 | $-0.17 | $-0.17 | $-0.17 | 1 |
| Q4 FY2026 | $-0.30 | $-0.30 | $-0.30 | 1 |
| Q3 FY2026 | $-0.28 | $-0.28 | $-0.28 | 2 |
| Q2 FY2026 | $-0.28 | $-0.28 | $-0.28 | 3 |
| Q1 FY2026 | $-0.29 | $-0.27 | $-0.25 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 14, 2026 | +11.1% | $11.65 | $11.85 | +1.72% |
| ▼ Q1 FY2026 | Feb 12, 2026 | -13.0% | $11.65 | $11.34 | -2.66% |
| ▲ Q4 FY2025 | Nov 14, 2025 | +37.1% | $13.15 | $13.16 | +0.08% |
| ▼ Q3 FY2025 | Sep 22, 2025 | -50.0% | $13.45 | $13.51 | +0.45% |
| ▲ Q2 FY2025 | May 14, 2025 | +33.3% | $13.18 | $13.58 | +3.03% |
| ▲ Q1 FY2025 | Feb 14, 2025 | +64.0% | $9.70 | $11.25 | +15.98% |
| ▲ Q4 FY2024 | Nov 14, 2024 | +21.3% | $10.44 | $10.40 | -0.38% |
| ▼ Q3 FY2024 | Sep 26, 2024 | -169.4% | $8.80 | $8.79 | -0.11% |
Q2 FY2026+1.72%
Report Date
May 14, 2026
EPS Beat/Miss
+11.1%
Price Before
$11.65
Price After
$11.85
Q1 FY2026-2.66%
Report Date
Feb 12, 2026
EPS Beat/Miss
-13.0%
Price Before
$11.65
Price After
$11.34
Q4 FY2025+0.08%
Report Date
Nov 14, 2025
EPS Beat/Miss
+37.1%
Price Before
$13.15
Price After
$13.16
Q3 FY2025+0.45%
Report Date
Sep 22, 2025
EPS Beat/Miss
-50.0%
Price Before
$13.45
Price After
$13.51
Q2 FY2025+3.03%
Report Date
May 14, 2025
EPS Beat/Miss
+33.3%
Price Before
$13.18
Price After
$13.58
Q1 FY2025+15.98%
Report Date
Feb 14, 2025
EPS Beat/Miss
+64.0%
Price Before
$9.70
Price After
$11.25
Q4 FY2024-0.38%
Report Date
Nov 14, 2024
EPS Beat/Miss
+21.3%
Price Before
$10.44
Price After
$10.40
Q3 FY2024-0.11%
Report Date
Sep 26, 2024
EPS Beat/Miss
-169.4%
Price Before
$8.80
Price After
$8.79
Avg Beat Reaction+4.09%
Avg Miss Reaction-0.77%
Beat Rate5 / 8 quarters
Largest Move+15.98% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BNTC ends December
Benitec Biopharma Inc. (BNTC) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-0.24 — beating the analyst consensus of $-0.27 by +11.1%. The next BNTC earnings date is expected around September 1, 2026.
Each quarter, investors track BNTC earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BNTC revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BNTC's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BNTC earnings · 5 questionsBenitec Biopharma Inc.'s next earnings report is expected around September 1, 2026. BNTC typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BNTC historically reports after market close (AMC).
BNTC earnings datewhen is BNTC earningsBNTC next earnings datewhen does BNTC report earningsBNTC earnings calendar
▸ Source: FMP · Benitec Biopharma Inc. SEC filings · US GAAP · Benitec Biopharma Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026